Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease

Gut

Volumn 53, Issue 1, 2004, Pages 70-77

  Di Sabatino, A ^a   Ciccocioppo, R ^c   Cinque, B ^b   Millimaggi, D ^b   Morera, R ^a   Ricevuti, L ^a   Cifone, M G ^b   Corazza, G R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE INHIBITOR; FAS LIGAND; FLUORESCEIN ISOTHIOCYANATE; INFLIXIMAB; LIPOCORTIN 5; MESALAZINE; NEUTRALIZING ANTIBODY; PROPIDIUM IODIDE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; APOPTOSIS; ARTICLE; BLOOD; CELL CULTURE; CELL DEATH; CELL ISOLATION; CELL KILLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DRUG ACTIVITY; DRUG EFFECT; DRUG INFUSION; DRUG SENSITIVITY; ENDOSCOPY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; INTESTINE BIOPSY; LAMINA PROPRIA; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STAINING; T LYMPHOCYTE;

ADULT; ANTIBODIES, MONOCLONAL; APOPTOSIS; CASPASE 3; CASPASES; CELLS, CULTURED; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0346461662     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.53.1.70     Document Type: Article

References (38)

1. Di Sabafino A, Corazza GR. Surviving too long in Crohn's disease. Gut 2001;49:6-8.
2. Sturm A, Fiocchi C. Life and death in the gut: more killing, less Crohn's. Gut 2002;50:148-9.
3. Fuss U, Marth T, Neurath MF, et al. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999;117:1078-88.
4. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-8.
5. Lügering A, Schmidt M, Lügering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
6. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
7. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
8. Present DH, Rutgeerts P, Targan SR, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
9. von Deventer SJH. Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology, 2001;121:1242-6.
10. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995;7:251-9.
11. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
12. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27-32.
13. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
14. Di Sabafino A, Ciccocioppo R, D'Alò S, et al. Intraepithelial and lamina propria lymphocytes show distinct patterns of apoptosis, whereas both the populations are active in Fas-based cytotoxicity in coeliac disease. Gut 2001;49:380-6.
15. Pronk GJ, Ramer K, Amiri P, et al. Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER. Science 1996;271:808-10.
16. van Engeland M, Nieland UW, Ramaehers FCS, et al. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998;31:1-9.
17. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
18. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51:289-98.
19. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;119:1148-57.
20. Reimund JM, Dumont S, Muller CD, et al. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 1997;40:475-80.
21. Bauditz J, Haemling J, Ortner M, et al. Treatment with rumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997;40:470-4.
22. Mouser JF, Hyams JS. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin Ther 1999;21:932-42.
23. Breese EJ, Michie CA, Nicholls S, et al. Tumour necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
24. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of rumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
25. + T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 1993;177:1575-85.
26. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999;116:557-65.
27. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001;15:463-73.
28. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
29. Dhein J, Walczac H, Baumler C, et al. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 1995;373:438-41.
30. Boirivant M, Pica R, De Maria R, et al. Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. J Clin Invest 1996;98:2616-22.
31. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081-90.
32. Sturm A, Mohr S, Fiocchi C. Critical role in the regulation of apoptosis and proliferation of mucosal T cells. Gastroenterology 2002;122:1334-45.
33. Kondo S, Shinomura Y, Miyazaki Y, et al. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res 2000;60:4328-30.
34. Komaki S, Kohno M, Matsuura N, et al. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum Genet 1998;103:435-40.
35. Shetty A, Forbes A. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease. Am J Pharmacogenomics 2002;2:215-21.
36. Stasi R, Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol 2002;116:334-7.
37. Papadaki HA, Kritikos HD, Valatas V, et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-α antibody therapy. Blood 2002;100:474-82.
38. Oshima S, Mima T, Sasai M, et al. Tumour necrosis factor-α (TNF-α) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNFα therapy for RA. Cytokine 2000;12:281-8.